<DOC>
	<DOC>NCT02760797</DOC>
	<brief_summary>This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of emactuzumab and RO7009789 administered in combination in participants with advanced solid tumors. This study will be conducted in two parts: dose escalation stage (Part 1) and an expansion stage (Part 2).</brief_summary>
	<brief_title>A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group performance status 0 or 1 Participants must have histologically confirmed diagnosis of locally advanced and/or metastatic triple negative breast cancer, ovarian cancer, gastric cancer, colorectal cancer, pancreatic cancer, melanoma or mesothelioma Radiologically measurable and clinically evaluable disease as per RECIST version 1.1 Life expectancy of greater than or equal to (&gt;=) 16 weeks Ability to comply with the collection of tumor biopsies; tumors must be accessible for biopsy Adequate bone marrow, liver, cardiac, and renal function Allergy or hypersensitivity to components of either study drug formulation Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening or prior radiographic assessments. Participants with radiographically stable, asymptomatic previously irradiated lesions are eligible provided Participant is &gt;= 4 weeks beyond completion of cranial irradiation and &gt;/= 3 weeks off of corticosteroid therapy Participants with leptomeningeal disease, Participants with metastases to the brain stem, midbrain, pons, medulla, or within 10 millimeters (mm) of the optic apparatus (optic nerves and chiasm) are excluded History of Human Immunodeficiency Virus (HIV) Participants with active hepatitis B, active hepatitis C, or active tuberculosis Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>